Entera Bio (ENTX) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Entera Bio (ENTX) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 30.6% versus a loss of 5.6%. Over five years, ENTX leads with a -3.6% price change compared with -53.6% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $575.5 million), about 1.0 times the size.
4D Molecular Therapeutics converts more of its revenue into profit, with a net margin of -164.4% versus -27235.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | FDMT |
|---|---|---|
| Share price | $3.31 | $10.23 |
| Market cap | $575.53M | $576.76M |
| 1-day change | +0.76% | -4.57% |
| YTD return | +70.36% | +36.40% |
| 1-year return | +30.63% | -5.63% |
| 5-year return | -3.64% | -53.61% |
| EPS (TTM) | $-0.40 | $-2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.00K | $85.21M |
| Revenue growth (YoY) | -76.80% | +230194.59% |
| Net income (latest FY) | $-11.44M | $-140.11M |
| Gross margin | 0.00% | — |
| Operating margin | -27450.00% | -187.24% |
| Net margin | -27235.71% | -164.43% |
| 52-week high | $4.20 | $16.93 |
| 52-week low | $0.91 | $6.96 |
| Distance from 52-week high | -21.31% | -39.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +195.01% | +174.58% |
| Average volume | 438.35K | 967.00K |
| Shares outstanding | 174.14M | 56.38M |
| Employees | 27 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed FDMT by 36.3 percentage points over the past year.
- 4D Molecular Therapeutics is more profitable, keeping -164.4 cents of every revenue dollar as net income versus -27235.7 cents for Entera Bio.
- 4D Molecular Therapeutics grew revenue faster in its latest fiscal year (+230194.59% vs -76.80%).
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
ENTX vs FDMT FAQ
Which is bigger, Entera Bio or 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $575.53M for Entera Bio (ENTX).
Which stock has performed better over the past year, ENTX or FDMT?
ENTX returned +30.63% over the past 12 months, compared with -5.63% for FDMT (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.